Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01277549 · ClinicalTrials.gov registry record
Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
A clinical trial, sponsored by Terumo BCT.
- Completed
- Registry status
- 71
- Enrollment target
NCT01277549: Completed study, sponsored by Terumo BCT.
NCT01277549 is a clinical trial that has completed, run by Terumo BCT. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01277549 has completed, sponsored by Terumo BCT.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy G-CSF (granulocyte colony stimulating factor) mobilized blood donors, respectively.
Primary Outcome
The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
Interventions
- DEVICE Mononuclear cell collection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-09 |
What the finished NCT01277549 record still lists
NCT01277549 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Mononuclear cell collection. is the first listed.
NCT01277549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01277549 about?
NCT01277549 is a clinical study titled "Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors". The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy G-CSF (granulocyte colony stimulat...
What is the current status of trial NCT01277549?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2011-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01277549?
The interventions under investigation include: Mononuclear cell collection. (DEVICE).
Who is sponsoring clinical trial NCT01277549?
This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia